GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (AMEX:IBIO) » Definitions » Beneish M-Score

iBio (IBIO) Beneish M-Score : -1.16 (As of Dec. 13, 2024)


View and export this data going back to 2008. Start your Free Trial

What is iBio Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.16 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for iBio's Beneish M-Score or its related term are showing as below:

IBIO' s Beneish M-Score Range Over the Past 10 Years
Min: -12.55   Med: -2.28   Max: 62.02
Current: -1.16

During the past 13 years, the highest Beneish M-Score of iBio was 62.02. The lowest was -12.55. And the median was -2.28.


iBio Beneish M-Score Historical Data

The historical data trend for iBio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Beneish M-Score Chart

iBio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.02 -0.97 0.06 - -

iBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.55 -7.90 - - -1.16

Competitive Comparison of iBio's Beneish M-Score

For the Biotechnology subindustry, iBio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iBio's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iBio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where iBio's Beneish M-Score falls into.



iBio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of iBio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 1.3915+0.892 * 3.5+0.115 * 0.8611
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1787+4.679 * -0.29453-0.327 * 0.4319
=-1.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0.175 + 0 + 0 = $0.18 Mil.
Gross Profit was 0 + 0.175 + 0 + 0 = $0.18 Mil.
Total Current Assets was $11.71 Mil.
Total Assets was $24.52 Mil.
Property, Plant and Equipment(Net PPE) was $6.10 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.21 Mil.
Selling, General, & Admin. Expense(SGA) was $10.93 Mil.
Total Current Liabilities was $3.47 Mil.
Long-Term Debt & Capital Lease Obligation was $3.28 Mil.
Net Income was -3.989 + -7.778 + -3.172 + -8.211 = $-23.15 Mil.
Non Operating Income was 0 + 0 + 1 + 0 = $1.00 Mil.
Cash Flow from Operations was -3.715 + -4.854 + -3.654 + -4.706 = $-16.93 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.05 + 0 + 0 + 0 = $0.05 Mil.
Gross Profit was 0.05 + 0 + 0 + 0 = $0.05 Mil.
Total Current Assets was $23.02 Mil.
Total Assets was $37.68 Mil.
Property, Plant and Equipment(Net PPE) was $7.24 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.20 Mil.
Selling, General, & Admin. Expense(SGA) was $17.48 Mil.
Total Current Liabilities was $20.71 Mil.
Long-Term Debt & Capital Lease Obligation was $3.30 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.175) / (0 / 0.05)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.05 / 0.05) / (0.175 / 0.175)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11.705 + 6.099) / 24.517) / (1 - (23.022 + 7.242) / 37.678)
=0.27381 / 0.196773
=1.3915

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.175 / 0.05
=3.5

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.204 / (1.204 + 7.242)) / (1.21 / (1.21 + 6.099))
=0.142553 / 0.165549
=0.8611

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(10.928 / 0.175) / (17.475 / 0.05)
=62.445714 / 349.5
=0.1787

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.278 + 3.469) / 24.517) / ((3.3 + 20.708) / 37.678)
=0.275197 / 0.637189
=0.4319

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-23.15 - 1 - -16.929) / 24.517
=-0.29453

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

iBio has a M-score of -1.16 signals that the company is likely to be a manipulator.


iBio Business Description

Traded in Other Exchanges
N/A
Address
11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Executives
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Felipe Duran officer: Interim CFO 8800 HSC PARKWAY, BRYAN TX 77807
William D Clark director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Evert B. Schimmelpennink director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd director, officer: CEO and Executive Chairman C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz officer: See Remarks 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux officer: Chief Operating Officer 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova director RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Gary Sender director C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Linda Washington Armstrong director 8800 HSC PARKWAY, BRYAN TX 77807
John Delta officer: Principal Accounting Officer 8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin officer: President C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney officer: Chief Financial Officer C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431